journal
Journals Expert Opinion on Therapeutic ...

Expert Opinion on Therapeutic Patents

https://read.qxmd.com/read/38648107/targeting-the-tgf-%C3%AE-signaling-pathway-an-updated-patent-review-2021-present
#1
REVIEW
Wenhao Guo, Hanwen Liu, Yong Yan, Di Wu, Hequan Yao, Kejiang Lin, Xuanyi Li
INTRODUCTION: The TGF-β signaling pathway is a complex network that plays a crucial role in regulating essential biological functions and is implicated in the onset and progression of multiple diseases. This review highlights the recent advancements in developing inhibitors targeting the TGF-β signaling pathway and their potential therapeutic applications in various diseases. AREA COVERED: The review discusses patents on active molecules related to the TGF-β signaling pathway, focusing on three strategies: TGF-β activity inhibition, blocking TGF-β receptor binding, and disruption of the signaling pathway using small molecule inhibitors...
April 22, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38588538/pcsk9-inhibitors-a-patent-review-2018-2023
#2
REVIEW
Enrico Mario Alessandro Fassi, Andrea Citarella, Marco Albani, Erica Ginevra Milano, Laura Legnani, Carmen Lammi, Alessandra Silvani, Giovanni Grazioso
No abstract text is available yet for this article.
April 8, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38578253/an-overview-on-recent-patents-and-technologies-on-nanoparticles-for-nucleic-acid-delivery
#3
REVIEW
Larissa Moraes Dos Santos Fonseca, Bruna Aparecida Souza Machado, Fabricia Oliveira Oliveira, Jânio Rodrigo de Jesus Santos, Jaqueline Wang da Silva, Katharine Valeria Saraiva Hodel, Brisa Gonçalves Rosatti, Claudio Damasceno Pinto, Milena Botelho Pereira Soares
INTRODUCTION: Nucleic acid-based therapeutics offer groundbreaking potential for treating genetic diseases and advancing next-generation vaccines. Despite their promise, challenges in efficient delivery persist due to the properties of nucleic acids. Nanoparticles (NPs) serve as vital carriers, facilitating effective delivery to target cells, and addressing these challenges. Understanding the global landscape of patents in this field is essential for fostering innovation and guiding decision-making for researchers, the pharmaceutical industry, and regulatory agencies...
April 5, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38578210/synthetic-lethality-targeting-smarca2-atpase-in-smarca4-deficient-tumors-a-review-of-patent-literature-from-2019-30-june-2023
#4
REVIEW
Kyle D Reichl, Esther C Y Lee, Ariamala Gopalsamy
INTRODUCTION: The multi-subunit SWI/SNF chromatin remodeling complex is a key epigenetic regulator for many cellular processes, and several subunits are found to be mutated in human cancers. The inactivating mutations of SMARCA4, the ATPase subunit of the complex, result in cellular dependency on the paralog SMARCA2 for survival. This observed synthetic lethal relationship posits targeting SMARCA2 in SMARCA4-deficient settings as an attractive therapeutic target in oncology. AREAS COVERED: This review covers patent literature disclosed during the 2019-30 June 2023 period which claim ATPase inhibitors and PROTAC degraders that bind to the ATPase domain of SMARCA2 and/or SMARCA4...
April 5, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38578180/biofilm-and-bacterial-membrane-vesicles-recent-advances
#5
REVIEW
Valentina Puca, Beatrice Marinacci, Benedetta Pellegrini, Floriana Campanile, Maria Santagati, Rossella Grande
INTRODUCTION: Bacterial Membrane Vesicles (MVs) play important roles in cell-to-cell communication and transport of several molecules. Such structures are essential components of Extracellular Polymeric Substances (EPS) biofilm matrix of many bacterial species displaying a structural function and a role in virulence and pathogenesis. AREAS COVERED: In this review were included original articles from the last ten years by searching the keywords 'biofilm' and 'vesicles' on PUBMED and Scopus databases...
April 5, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38573177/targeting-the-relaxin-3-rxfp3-system-a-patent-review-for-the-last-two-decades
#6
REVIEW
Md Toufiqur Rahman, Hetti Handi Chaminda Lakmal, Javeena Hussain, Chunyang Jin
INTRODUCTION: The neuropeptide relaxin-3/RXFP3 system belongs to the relaxin/insulin superfamily and is involved in many important physiological processes, such as stress responses, appetite control, and motivation for reward. Although relaxin-3 is the endogenous agonist for RXFP3, it can also bind to and activate RXFP1 and RXFP4. Consequently, research has been focused on the development of RXFP3-specific peptides and small-molecule ligands to validate the relaxin-3/RXFP3 system as a novel drug target...
April 4, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38557273/targeting-the-pi3k-akt-signaling-pathway-in-anticancer-research-a-recent-update-on-inhibitor-design-and-clinical-trials-2020-2023
#7
REVIEW
Dima A Sabbah, Rima Hajjo, Sanaa K Bardaweel, Haizhen A Zhong
INTRODUCTION: Recent years have witnessed great achievements in drug design and development targeting the phosphatidylinositol 3-kinase/protein kinase-B (PI3K/AKT) signaling pathway, a pathway central to cell growth and proliferation. The nearest neighbor protein-protein interaction networks for PI3K and AKT show the interplays between these target proteins which can be harnessed for drug discovery. In this review, we discuss the drug design and clinical development of inhibitors of PI3K/AKT in the past three years...
April 1, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38557201/a-patent-review-on-hmgb1-inhibitors-for-the-treatment-of-liver-diseases
#8
REVIEW
Richa Raj, Pingping Shen, Boyang Yu, Jian Zhang
INTRODUCTION: HMGB1 is a non-histone chromatin protein released or secreted from cells in response to tissue damage or infection. Extracellular HMGB1, as a crucial immunomodulatory factor, binds with several different receptors to innate inflammatory responses that aggravate acute and chronic liver diseases. The increased levels of HMGB1 have been reported in various liver diseases, highlighting that it represents a potential biomarker and druggable target for therapeutic development...
April 1, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38506448/carbonic-anhydrase-and-bacterial-metabolism-a-chance-for-antibacterial-drug-discovery
#9
REVIEW
Clemente Capasso, Claudiu T Supuran
INTRODUCTION: Carbonic anhydrases (CAs, EC 4.2.1.1) play a pivotal role in the regulation of carbon dioxide , bicarbonate, and hydrogen ions within bacterial cells, ensuring pH homeostasis and facilitating energy production. We conducted a systematic literature search (PubMed, Web of Science, and Google Scholar) to examine the intricate interplay between CAs and bacterial metabolism, revealing the potential of CA inhibitors (CAIs) as innovative therapeutic agents against pathogenic bacteria...
March 20, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38501260/peroxisome-proliferator-activated-receptor-agonists-and-antagonists-an-updated-patent-review-2020-2023
#10
REVIEW
Barbara De Filippis, Arianna Granese, Alessandra Ammazzalorso
INTRODUCTION: The search for novel compounds targeting Peroxisome Proliferator-Activated Receptors (PPARs) is currently ongoing, starting from the previous successfully identification of selective, dual or pan agonists. In last years, researchers' efforts are mainly paid to the discovery of PPARγ and δ modulators, both agonists and antagonists, selective or with a dual-multitarget profile. Some of these compounds are currently under clinical trials for the treatment of primary biliary cirrhosis, nonalcoholic fatty liver disease, hepatic, and renal diseases...
March 19, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38450537/targeting-the-egfr-ras-raf-signaling-pathway-in-anticancer-research-a-recent-update-on-inhibitor-design-and-clinical-trials-2020-2023
#11
REVIEW
Rima Hajjo, Dima A Sabbah, Sanaa K Bardaweel, Haizhen A Zhong
INTRODUCTION: Recent years have seen significant strides in drug developmenttargeting the EGFR/RAS/RAF signaling pathway which is critical forcell growth and proliferation. Protein-protein interaction networksamong EGFR, RAS, and RAF proteins offer insights for drug discovery. This review discusses the drug design and development efforts ofinhibitors targeting these proteins over the past 3 years, detailingtheir structures, selectivity, efficacy, and combination therapy.Strategies to combat drug resistance and minimize toxicities areexplored, along with future research directions...
March 12, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38465537/successes-and-challenges-in-the-development-of-bd1-selective-bet-inhibitors-a-patent-review
#12
JOURNAL ARTICLE
Monica Viviano, Alessandra Cipriano, Emanuele Fabbrizi, Alessandra Feoli, Sabrina Castellano, Gianluca Sbardella, Antonello Mai, Ciro Milite, Dante Rotili
INTRODUCTION: Bromodomain and ExtraTerminal (BET) domain proteins are transcriptional cofactors that, recognizing acetylated lysines of histone and non-histone proteins, can modulate gene expression. The BET family consists of four members, each of which contains two bromodomains (BD1 and BD2) able to recognize the acetylated mark. Pan-BET inhibitors (BETi) have shown a promising anticancer potential in many clinical trials; however, their further development has been in part hampered by the side effects due to their lack of selectivity...
March 11, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38446009/recent-developments-of-agents-targeting-vibrio-cholerae-patents-and-literature-data
#13
REVIEW
Francesco Melfi, Simone Carradori, Noemi Mencarelli, Cristina Campestre, Arianna Granese, Mattia Mori
INTRODUCTION: Vibrio cholerae bacteria cause an infection characterized by acute diarrheal illness in the intestine. Cholera is sustained by people swallowing contaminated food or water. Even though symptoms can be mild, if untreated disease becomes severe and life-threatening, especially in low-income countries. AREAS COVERED: After a description of the most recent literature on the pathophysiology of this infection, we searched for patents and literature articles following the PRISMA guidelines, filtering the results disclosed from 2020 to present...
March 6, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38445468/therapeutic-cysteine-protease-inhibitors-a-patent-review-2018-present
#14
REVIEW
Giulia Barchielli, Antonella Capperucci, Damiano Tanini
INTRODUCTION: Cysteine proteases are involved in a broad range of biological functions, ranging from extracellular matrix turnover to immunity. Playing an important role in the onset and progression of several diseases, including cancer, immune-related and neurodegenerative disease, viral and parasitic infections, cysteine proteases represent an attractive drug target for the development of therapeutic tools. AREAS COVERED: Recent scientific and patent literature focusing on the design and study of cysteine protease inhibitors with potential therapeutic application has been reviewed...
March 6, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38441084/recent-developments-of-hsp90-inhibitors-an-updated-patent-review-2020-present
#15
REVIEW
Jianfeng Liu, Huangliang Shu, Qinxin Xia, Qidong You, Lei Wang
INTRODUCTION: The 90-kDa heat shock protein (HSP90) functions as a molecular chaperone, it assumes a significant role in diseases such as cancer, inflammation, neurodegeneration, and infection. Therefore, the research and development of HSP90 inhibitors have garnered considerable attention. AREAS COVERED: The primary references source for this review is patents obtained from Scifinder, encompassing patents on HSP90 inhibitors from the period of 2020 to 2023.This review includes a thorough analysis of their structural attributes, pharmacological properties, and potential clinical utilities...
March 5, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38439633/photodynamic-therapy-alone-or-in-combination-to-counteract-bacterial-infections
#16
REVIEW
Sébastien Clément, Jean-Yves Winum
INTRODUCTION: Antibacterial photodynamic therapy presents a promising alternative to antibiotics, with potential against multidrug-resistant bacteria, offering broad-spectrum action, reduced resistance risk, and improved tissue selectivity. AREAS COVERED: This manuscript reviews patent literature in the field of antibacterial photodynamic therapy through the period of 2019-2023. All data are from the US and European patent databases and SciFinder. EXPERT OPINION: Antibacterial photodynamic therapy (PDT) is an appealing approach for treating bacterial infections, especially biofilm-related ones, by releasing reactive oxygen species (ROS) upon light activation...
March 4, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38308658/patented-farnesoid-x-receptor-modulators-a-review-2019-present
#17
REVIEW
Antimo Gioiello, Emiliano Rosatelli, Bruno Cerra
INTRODUCTION: The Farnesoid X receptor (FXR) is a key transcription factor that is involved in the bile acid signaling network. The modulation of the FXR activity influences glucose and lipid homeostasis, reduces obesity and insulin resistance, as well as it regulates the pathogenesis of inflammatory and metabolic disorders. FXR ligands have therefore emerged in drug discovery as promising therapeutic agents for the prevention and treatment of gastrointestinal and liver diseases, including cancer...
February 26, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38165255/the-patent-review-of-the-biological-activity-of-tropane-containing-compounds
#18
REVIEW
Thoraya A Farghaly, Ghada S Masaret, Hanan Gaber Abdulwahab
INTRODUCTION: Tropane-derived medications have historically played a substantial role in pharmacotherapy. Both natural and synthetic derivatives of tropane find application in addressing diverse medical conditions. Prominent examples of tropane-based drugs include hyoscine butylbromide, recognized for its antispasmodic properties, atropine, employed as a mydriatic, maraviroc, known for its antiviral effects. trospium chloride, utilized as a spasmolytic for overactive bladder, and ipratropium, a bronchodilator...
January 2, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38131310/therapeutic-applications-of-thymosin-peptides-a-patent-landscape-2018-present
#19
REVIEW
Michael Quagliata, Anna Maria Papini, Paolo Rovero
INTRODUCTION: Thymosins are small proteins found mainly in the thymus. They are involved in several biological processes, including immunoregulation, angiogenesis, and anti-inflammatory activity. Due to these multiple activities, thymosins are widely used as therapeutics. In fact, these peptides have shown interesting results in the treatment of eye disorders, anticancer therapy, and dysregulated immune disorders. AREA COVERED: We analyzed the thymosins therapeutic patent landscape describing the most significant patents published after 2018 and originally written in English, classified according to the different type of functions and diseases...
December 22, 2023: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38115554/part-ii-an-update-of-schiff-bases-synthesis-and-applications-in-medicinal-chemistry-a-patent-review-2016-2023
#20
REVIEW
Hafiza Amna Younus, Faiza Saleem, Abdul Hameed, Mariya Al-Rashida, Raed A Al-Qawasmeh, Mohamed El-Naggar, Sobia Rana, Muhammad Saeed, Khalid Mohammed Khan
INTRODUCTION: Schiff bases are compounds with characteristic features of azomethine linkage (-C=N-). Schiff bases are capable of coordinating with metal ions via azomethine nitrogen. Schiff base derivatives and their metal complexes are known for intriguing novel therapeutic properties. In organic synthesis, the Schiff base reaction is prime in creating the C-N bond. Synthetic accessibility and structural diversity are the salient features for facile synthesis of Schiff base hybrids via a condensation reaction between an aldehyde/ketone and primary amines...
December 19, 2023: Expert Opinion on Therapeutic Patents
journal
journal
32389
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.